Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714

NCT03691077 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis
Relapse
Primary Progressive Multiple Sclerosis

Interventions

DRUG: Ocrelizumab

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]
[object Object]